BMC cancer · 2026
Exploring the impact of melatonin on cancer-related fatigue: a dose-response meta-analysis with GRADE evidence evaluation.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Etesamnia Sajjad, Nasiraie-Moghadam Mahdiyar, Mostafazadeh Pariya, Jowshan Mohammad-Reza, Roudini Kamran, Miri Seyed Rohollah, Jahan-Mihan Alireza, Haghighi Alireza, Ebrahimpour-Koujan Soraiya
Аннотация
BACKGROUND: Cancer-related fatigue (CRF) is a prevalent and debilitating symptom among patients undergoing cancer treatment, yet its management remains a clinical challenge. Previous studies evaluating the role of melatonin in CRF have yielded inconsistent findings. This meta-analysis aimed to assess the overall effect of melatonin supplementation on fatigue and to explore potential dose-response relationships.
METHODS: A systematic literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar up to 24 August 2025. Randomized controlled trials comparing melatonin with a placebo in adult cancer patients were included. SMDs with 95% CIs were calculated using a random-effects model. Nonlinear and linear dose-response analyses were conducted, and certainty of evidence was evaluated with the GRADE approach.
RESULTS: Twelve trials (18 effect sizes, n = 1,977) met the inclusion criteria. Pooled analysis showed a significant reduction in fatigue scores with melatonin supplementation (SMD: -0.45; 95% CI: -0.69, - 0.20; P < 0.001). Dose-response analysis revealed a significant inverse association for melatonin doses between 5 and 15 mg/day (P-nonlinearity = 0.03). Short-term interventions (≤ 4 weeks) demonstrated greater benefit, whereas longer durations showed no consistent effects. However, substantial heterogeneity (I² = 78%) and very low certainty of evidence limit the robustness of these findings.
CONCLUSIONS: Melatonin supplementation may reduce fatigue in cancer patients, particularly at doses of 5-15 mg/day and with short-term use. Nonetheless, the certainty of evidence remains very low, highlighting the need for high-quality, large-scale RCTs with standardized methodologies to validate these results.
METHODS: A systematic literature search was performed in PubMed, Scopus, Web of Science, and Google Scholar up to 24 August 2025. Randomized controlled trials comparing melatonin with a placebo in adult cancer patients were included. SMDs with 95% CIs were calculated using a random-effects model. Nonlinear and linear dose-response analyses were conducted, and certainty of evidence was evaluated with the GRADE approach.
RESULTS: Twelve trials (18 effect sizes, n = 1,977) met the inclusion criteria. Pooled analysis showed a significant reduction in fatigue scores with melatonin supplementation (SMD: -0.45; 95% CI: -0.69, - 0.20; P < 0.001). Dose-response analysis revealed a significant inverse association for melatonin doses between 5 and 15 mg/day (P-nonlinearity = 0.03). Short-term interventions (≤ 4 weeks) demonstrated greater benefit, whereas longer durations showed no consistent effects. However, substantial heterogeneity (I² = 78%) and very low certainty of evidence limit the robustness of these findings.
CONCLUSIONS: Melatonin supplementation may reduce fatigue in cancer patients, particularly at doses of 5-15 mg/day and with short-term use. Nonetheless, the certainty of evidence remains very low, highlighting the need for high-quality, large-scale RCTs with standardized methodologies to validate these results.